Profile data is unavailable for this security.
About the company
Theracryf PLC, formerly Evgen Pharma plc, is a clinical-stage therapeutics company. The Company is engaged in developing a new generation of therapeutics in oncology and behavioral brain disorders. Its pipeline and lead compound SFX-01 is derived from its proprietary Sulforadex technology. Its Sulforadex technology synthesizes sulforaphane into an active, stable, and solid form pharmaceutical ingredient, unlocking its medical and commercial potential. SFX-01 is a complex of sulforaphane and alpha-cyclodextrin formulated as a stable tablet. The Company has a candidate orexin 1 antagonist at late preclinical stage targeting addictive behaviors. It also has a candidate molecule DAT inhibitor at late preclinical stage targeting fatigue and narcolepsy.
- Revenue in GBP (TTM)838.00k
- Net income in GBP-3.35m
- Incorporated2014
- Employees7.00
- LocationTheraCryf PLCSuite 24G13 - Block 24 Alderley ParkCongleton Road, Nether AlderleyNETHERTON SK10 4TGUnited KingdomGBR
- Phone+44 16 2531 5090
- Websitehttps://evgen.com/
Mergers & acquisitions
Acquired company | TCF:LSE since announced | Transaction value |
---|---|---|
Chronos Therapeutics Ltd | -21.05% | 4.33m |
Peer analysis
Company | Revenue (TTM) | Net income (TTM) |
---|---|---|
Nuformix PLC | 0.00 | -436.95k |
Oxford Cannabinoid Tchnlgs Hldngs PLC | 0.00 | -4.24m |
ReNeuron Group Plc | 249.00k | -5.07m |
N4 Pharma PLC | 1.95k | -1.28m |
Hellenic Dynamics PLC | -100.00bn | -100.00bn |
ValiRx Plc | 9.60k | -2.04m |
TheraCryf PLC | 838.00k | -3.35m |
Fusion Antibodies PLC | 1.58m | -2.84m |
IXICO PLC | 6.67m | -1.18m |
BSF Enterprise PLC | 12.94k | -1.50m |
Cizzle Biotechnology Holdings PLC | 0.00 | -1.72m |
Genflow Biosciences PLC | 0.00 | -1.63m |
Institutional shareholders
Holder | Shares | % Held |
---|---|---|
Rathbones Investment Management Ltd.as of 05 Apr 2024 | 25.79m | 6.04% |
Octopus Investments Ltd.as of 05 Apr 2024 | 21.88m | 5.12% |
Vulpes Investment Management Pte Ltd.as of 11 Apr 2024 | 20.55m | 4.81% |
AXA Investment Managers UK Ltd.as of 27 Dec 2023 | 13.40m | 3.14% |
Chelverton Asset Management Ltd.as of 05 Jun 2023 | 12.50m | 2.93% |
RAB Capital Ltd. (Investment Management)as of 05 Jun 2023 | 8.75m | 2.05% |
Hargreaves Lansdown Asset Management Ltd.as of 01 Jun 2023 | 7.77m | 1.82% |
Jarvis Investment Management Ltd.as of 01 Jun 2023 | 4.55m | 1.06% |
IG Markets Ltd.as of 01 Jun 2023 | 3.89m | 0.91% |
Rowan Dartington & Co. Ltd. (Broker)as of 01 Jun 2023 | 3.69m | 0.86% |